Abstract：Objective To evaluate the efficacy and safety of bevacizumab combined with paclitaxel and carboplatin（TC）chemotherapy in patients with ovarian cancer after laparoscopic surgery, providing a reference for the optimization of clinical treatment strategies. Methods A total of 136 patients who underwent laparoscopic radical ovarian cancer resection at Baotou Central Hospital from March 2023 to March 2025 were selected. The patients were randomly divided into two groups of 68 patients in each group using a random number table. The control group received TC chemotherapy, while the study group received bevacizumab combined with TC chemotherapy. Both groups received six cycles of treatment, with each cycle lasting 21 days. The short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors. The serum tumor marker levels before and after treatment, the incidence of adverse reactions, and the quality of life scores were compared between the two groups. Results The objective response rate in the study group was significantly higher than that in the control group（χ2＝4.253, P＝0.033）. After treatment, serum tumor marker levels in the study group were significantly lower than those in the control group（t＝20.454, 11.825, 18.555, all P＜0.001）. The quality of life scores in the study group were significantly higher than those in the control group after treatment （t＝5.782, 6.371, 6.954, all P＜0.001）. There was no significant difference in the total incidence of adverse reactions between the two groups（χ2＝0.160, P＝0.689）.Conclusion Bevacizumab combined with TC chemotherapy can significantly improve the clinical efficacy and quality of life in patients with ovarian cancer after laparoscopic surgery. It also effectively reduces tumor marker levels without increasing the risk of adverse reactions. This regimen is safe and effective, and has important clinical application value.